RU2143432C1 - Новые производные хинуклидина и медицинские композиции, содержащие их - Google Patents
Новые производные хинуклидина и медицинские композиции, содержащие их Download PDFInfo
- Publication number
- RU2143432C1 RU2143432C1 RU97112907/04A RU97112907A RU2143432C1 RU 2143432 C1 RU2143432 C1 RU 2143432C1 RU 97112907/04 A RU97112907/04 A RU 97112907/04A RU 97112907 A RU97112907 A RU 97112907A RU 2143432 C1 RU2143432 C1 RU 2143432C1
- Authority
- RU
- Russia
- Prior art keywords
- group
- tetrahydro
- quinuclidinyl
- isoquinoline carboxylate
- groups
- Prior art date
Links
- 150000008584 quinuclidines Chemical class 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 title description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 78
- 125000005843 halogen group Chemical group 0.000 claims abstract description 26
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims abstract description 19
- 230000003551 muscarinic effect Effects 0.000 claims abstract description 15
- 239000002253 acid Substances 0.000 claims abstract description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 10
- 150000007513 acids Chemical class 0.000 claims abstract description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims abstract description 6
- 125000002541 furyl group Chemical group 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 6
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims abstract description 4
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 4
- SOPZDIWUILYOQG-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl 1-(4-methylphenyl)-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1=CC(C)=CC=C1C1C2=CC=CC=C2CCN1C(=O)OC1C(CC2)CCN2C1 SOPZDIWUILYOQG-UHFFFAOYSA-N 0.000 claims description 2
- PLSRRXPJOWNGME-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl 1-(furan-2-yl)-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1N(CC2)CCC2C1OC(=O)N1CCC2=CC=CC=C2C1C1=CC=CO1 PLSRRXPJOWNGME-UHFFFAOYSA-N 0.000 claims description 2
- FBOUYBDGKBSUES-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl 1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1N(CC2)CCC2C1OC(=O)N1CCC2=CC=CC=C2C1C1=CC=CC=C1 FBOUYBDGKBSUES-UHFFFAOYSA-N 0.000 claims description 2
- OPGPIFMCCIAMNE-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl 1-(4-chlorophenyl)-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1=CC(Cl)=CC=C1C1C2=CC=CC=C2CCN1C(=O)OC1C(CC2)CCN2C1 OPGPIFMCCIAMNE-UHFFFAOYSA-N 0.000 claims 1
- CEYITZYIKGLXEN-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl 1-(4-fluorophenyl)-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1=CC(F)=CC=C1C1C2=CC=CC=C2CCN1C(=O)OC1C(CC2)CCN2C1 CEYITZYIKGLXEN-UHFFFAOYSA-N 0.000 claims 1
- QQCOYFDBDPKTTK-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl 1-(furan-3-yl)-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1N(CC2)CCC2C1OC(=O)N1CCC2=CC=CC=C2C1C=1C=COC=1 QQCOYFDBDPKTTK-UHFFFAOYSA-N 0.000 claims 1
- FCXWHPXCAHMELT-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl 1-cyclohexyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1N(CC2)CCC2C1OC(=O)N1CCC2=CC=CC=C2C1C1CCCCC1 FCXWHPXCAHMELT-UHFFFAOYSA-N 0.000 claims 1
- FZSIBWFUOSPJKQ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl 1-pyridin-4-yl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1N(CC2)CCC2C1OC(=O)N1CCC2=CC=CC=C2C1C1=CC=NC=C1 FZSIBWFUOSPJKQ-UHFFFAOYSA-N 0.000 claims 1
- GVMGFZJINUTVNQ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl 1-thiophen-2-yl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1N(CC2)CCC2C1OC(=O)N1CCC2=CC=CC=C2C1C1=CC=CS1 GVMGFZJINUTVNQ-UHFFFAOYSA-N 0.000 claims 1
- JKZSORGVLCRTAY-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl 1-thiophen-3-yl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1N(CC2)CCC2C1OC(=O)N1CCC2=CC=CC=C2C1C=1C=CSC=1 JKZSORGVLCRTAY-UHFFFAOYSA-N 0.000 claims 1
- UANSQQFYKHHDJM-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]naphthalene-1-carboxamide Chemical compound C1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC=CC2=C1 UANSQQFYKHHDJM-KRWDZBQOSA-N 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 7
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000029087 digestion Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- -1 polyethylene Polymers 0.000 description 100
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
- 239000007858 starting material Substances 0.000 description 28
- 102000005962 receptors Human genes 0.000 description 27
- 108020003175 receptors Proteins 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 238000012360 testing method Methods 0.000 description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 22
- 239000000460 chlorine Substances 0.000 description 22
- 238000000921 elemental analysis Methods 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000003921 oil Substances 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 17
- 125000003545 alkoxy group Chemical group 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 12
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 12
- 125000003282 alkyl amino group Chemical group 0.000 description 12
- 125000003277 amino group Chemical group 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 125000001072 heteroaryl group Chemical group 0.000 description 10
- 125000005842 heteroatom Chemical group 0.000 description 10
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000008602 contraction Effects 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- 125000004434 sulfur atom Chemical group 0.000 description 8
- 239000013078 crystal Substances 0.000 description 7
- 125000000392 cycloalkenyl group Chemical group 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 241000700157 Rattus norvegicus Species 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000012442 inert solvent Substances 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- IVLICPVPXWEGCA-ZETCQYMHSA-N (3r)-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1CC2[C@@H](O)CN1CC2 IVLICPVPXWEGCA-ZETCQYMHSA-N 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- 229930003347 Atropine Natural products 0.000 description 4
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 206010036018 Pollakiuria Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 4
- 229960000396 atropine Drugs 0.000 description 4
- 230000036471 bradycardia Effects 0.000 description 4
- 208000006218 bradycardia Diseases 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 4
- 230000001020 rhythmical effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- DOAKXPDAEYUFEQ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl carbonochloridate;hydrochloride Chemical compound Cl.C1CC2C(OC(=O)Cl)CN1CC2 DOAKXPDAEYUFEQ-UHFFFAOYSA-N 0.000 description 3
- IVLICPVPXWEGCA-UHFFFAOYSA-N 3-quinuclidinol Chemical compound C1C[C@@H]2C(O)C[N@]1CC2 IVLICPVPXWEGCA-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010006458 Bronchitis chronic Diseases 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 238000007126 N-alkylation reaction Methods 0.000 description 3
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 208000023819 chronic asthma Diseases 0.000 description 3
- 208000007451 chronic bronchitis Diseases 0.000 description 3
- 201000009151 chronic rhinitis Diseases 0.000 description 3
- DKKVDRQVNMALLN-QGZVFWFLSA-N ethyl (1r)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1([C@@H]2C3=CC=CC=C3CCN2C(=O)OCC)=CC=CC=C1 DKKVDRQVNMALLN-QGZVFWFLSA-N 0.000 description 3
- DKKVDRQVNMALLN-KRWDZBQOSA-N ethyl (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(=O)OCC)=CC=CC=C1 DKKVDRQVNMALLN-KRWDZBQOSA-N 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000001525 receptor binding assay Methods 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- PRTRSEDVLBBFJZ-HNNXBMFYSA-N (1s)-1-phenyl-1,2,3,4-tetrahydroisoquinoline Chemical compound C1([C@H]2C3=CC=CC=C3CCN2)=CC=CC=C1 PRTRSEDVLBBFJZ-HNNXBMFYSA-N 0.000 description 2
- IVLICPVPXWEGCA-SSDOTTSWSA-N (3s)-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1CC2[C@H](O)CN1CC2 IVLICPVPXWEGCA-SSDOTTSWSA-N 0.000 description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N 1,1-Diethoxyethane Chemical compound CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010063057 Cystitis noninfective Diseases 0.000 description 2
- 208000008967 Enuresis Diseases 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 2
- 206010029279 Neurogenic bladder Diseases 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 201000003139 chronic cystitis Diseases 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- KRRRZOJBDDXSJH-UHFFFAOYSA-N ethyl 1-(4-fluorophenyl)-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound CCOC(=O)N1CCC2=CC=CC=C2C1C1=CC=C(F)C=C1 KRRRZOJBDDXSJH-UHFFFAOYSA-N 0.000 description 2
- QAXCBRJQYZBJDL-UHFFFAOYSA-N ethyl 1-(4-methylphenyl)-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound CCOC(=O)N1CCC2=CC=CC=C2C1C1=CC=C(C)C=C1 QAXCBRJQYZBJDL-UHFFFAOYSA-N 0.000 description 2
- YQAJSAMQWHXYSF-UHFFFAOYSA-N ethyl 1-(furan-2-yl)-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound CCOC(=O)N1CCC2=CC=CC=C2C1C1=CC=CO1 YQAJSAMQWHXYSF-UHFFFAOYSA-N 0.000 description 2
- QZMPGWLDGBSZGI-UHFFFAOYSA-N ethyl 1-(furan-3-yl)-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound CCOC(=O)N1CCC2=CC=CC=C2C1C=1C=COC=1 QZMPGWLDGBSZGI-UHFFFAOYSA-N 0.000 description 2
- ANRCISSCKRKAHW-UHFFFAOYSA-N ethyl 1-benzyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound CCOC(=O)N1CCC2=CC=CC=C2C1CC1=CC=CC=C1 ANRCISSCKRKAHW-UHFFFAOYSA-N 0.000 description 2
- UBFZHIAFYLMJOJ-UHFFFAOYSA-N ethyl 1-cyclohexyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound CCOC(=O)N1CCC2=CC=CC=C2C1C1CCCCC1 UBFZHIAFYLMJOJ-UHFFFAOYSA-N 0.000 description 2
- DKKVDRQVNMALLN-UHFFFAOYSA-N ethyl 1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound CCOC(=O)N1CCC2=CC=CC=C2C1C1=CC=CC=C1 DKKVDRQVNMALLN-UHFFFAOYSA-N 0.000 description 2
- YIFIMIQBCXQJRS-UHFFFAOYSA-N ethyl 1-pyridin-4-yl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound CCOC(=O)N1CCC2=CC=CC=C2C1C1=CC=NC=C1 YIFIMIQBCXQJRS-UHFFFAOYSA-N 0.000 description 2
- BYCDIILVONDENH-UHFFFAOYSA-N ethyl 1-thiophen-2-yl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound CCOC(=O)N1CCC2=CC=CC=C2C1C1=CC=CS1 BYCDIILVONDENH-UHFFFAOYSA-N 0.000 description 2
- SMHCPBIVKAOIRG-UHFFFAOYSA-N ethyl 1-thiophen-3-yl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound CCOC(=O)N1CCC2=CC=CC=C2C1C=1C=CSC=1 SMHCPBIVKAOIRG-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical group C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- PKTSKJGEVZPXTM-UHFFFAOYSA-N methyl 1-phenyl-1,3-dihydroisoindole-2-carboxylate Chemical compound COC(=O)N1CC2=CC=CC=C2C1C1=CC=CC=C1 PKTSKJGEVZPXTM-UHFFFAOYSA-N 0.000 description 2
- 239000003681 muscarinic M3 receptor antagonist Substances 0.000 description 2
- 230000001272 neurogenic effect Effects 0.000 description 2
- 208000005346 nocturnal enuresis Diseases 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 208000026451 salivation Diseases 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 208000014001 urinary system disease Diseases 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- PRTRSEDVLBBFJZ-OAHLLOKOSA-N (1r)-1-phenyl-1,2,3,4-tetrahydroisoquinoline Chemical compound C1([C@@H]2C3=CC=CC=C3CCN2)=CC=CC=C1 PRTRSEDVLBBFJZ-OAHLLOKOSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- YRYCIFUZSUMAAY-UHFFFAOYSA-N (RS)-1-benzyl-1,2,3,4-tetrahydroisoquinoline Chemical compound N1CCC2=CC=CC=C2C1CC1=CC=CC=C1 YRYCIFUZSUMAAY-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- UIBYAOPNXNPUEU-UHFFFAOYSA-N 1-(4-chlorophenyl)-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC(Cl)=CC=C1C1C2=CC=CC=C2CCN1 UIBYAOPNXNPUEU-UHFFFAOYSA-N 0.000 description 1
- KLZUHSZHUXFLET-UHFFFAOYSA-N 1-(4-chlorophenyl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid Chemical compound OC(=O)N1CCC2=CC=CC=C2C1C1=CC=C(Cl)C=C1 KLZUHSZHUXFLET-UHFFFAOYSA-N 0.000 description 1
- MKPFRVUDEFFJHS-UHFFFAOYSA-N 1-(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC(F)=CC=C1C1C2=CC=CC=C2CCN1 MKPFRVUDEFFJHS-UHFFFAOYSA-N 0.000 description 1
- OMRKUZDQUXNJDA-UHFFFAOYSA-N 1-(4-methylphenyl)-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC(C)=CC=C1C1C2=CC=CC=C2CCN1 OMRKUZDQUXNJDA-UHFFFAOYSA-N 0.000 description 1
- NTXMEXFAECISTB-UHFFFAOYSA-N 1-(furan-2-yl)-1,2,3,4-tetrahydroisoquinoline Chemical compound N1CCC2=CC=CC=C2C1C1=CC=CO1 NTXMEXFAECISTB-UHFFFAOYSA-N 0.000 description 1
- JPAXWAVQOCMTDS-UHFFFAOYSA-N 1-(furan-3-yl)-1,2,3,4-tetrahydroisoquinoline Chemical compound N1CCC2=CC=CC=C2C1C=1C=COC=1 JPAXWAVQOCMTDS-UHFFFAOYSA-N 0.000 description 1
- ZLXHPJWSAJBXPV-WLHGVMLRSA-N 1-azabicyclo[2.2.2]octan-3-yl 1-(4-chlorophenyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(Cl)=CC=C1C1C2=CC=CC=C2CCN1C(=O)OC1C(CC2)CCN2C1 ZLXHPJWSAJBXPV-WLHGVMLRSA-N 0.000 description 1
- QVJDPQPQRZODAN-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl 1-benzyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1N(CC2)CCC2C1OC(=O)N1CCC2=CC=CC=C2C1CC1=CC=CC=C1 QVJDPQPQRZODAN-UHFFFAOYSA-N 0.000 description 1
- WMJTZVTXTCGPDB-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl 1-phenyl-1,3-dihydroisoindole-2-carboxylate Chemical compound C1N(CC2)CCC2C1OC(=O)N1CC2=CC=CC=C2C1C1=CC=CC=C1 WMJTZVTXTCGPDB-UHFFFAOYSA-N 0.000 description 1
- NJMWHPNSMADYRP-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl 1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(CC2)CCC2C1OC(=O)N1CCC2=CC=CC=C2C1C1=CC=CC=C1 NJMWHPNSMADYRP-UHFFFAOYSA-N 0.000 description 1
- RLJRZDQVFNXOCL-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl 1-pyridin-4-yl-3,4-dihydro-1h-isoquinoline-2-carboxylate;dihydrochloride Chemical compound Cl.Cl.C1N(CC2)CCC2C1OC(=O)N1CCC2=CC=CC=C2C1C1=CC=NC=C1 RLJRZDQVFNXOCL-UHFFFAOYSA-N 0.000 description 1
- JOAAQVCRCUPTMU-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl 1-thiophen-2-yl-3,4-dihydro-1h-isoquinoline-2-carboxylate;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(CC2)CCC2C1OC(=O)N1CCC2=CC=CC=C2C1C1=CC=CS1 JOAAQVCRCUPTMU-UHFFFAOYSA-N 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-O 1-azoniabicyclo[2.2.2]octane Chemical compound C1CC2CC[NH+]1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-O 0.000 description 1
- 125000006083 1-bromoethyl group Chemical group 0.000 description 1
- 125000001478 1-chloroethyl group Chemical group [H]C([H])([H])C([H])(Cl)* 0.000 description 1
- OMYOTQLWOQIIKW-UHFFFAOYSA-N 1-cyclohexyl-1,2,3,4-tetrahydroisoquinoline Chemical compound C1CCCCC1C1C2=CC=CC=C2CCN1 OMYOTQLWOQIIKW-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
- FDJKLIVKKYFLSA-UHFFFAOYSA-N 1-oxido-1-azoniabicyclo[2.2.2]octane Chemical compound C1CC2CC[N+]1([O-])CC2 FDJKLIVKKYFLSA-UHFFFAOYSA-N 0.000 description 1
- PRTRSEDVLBBFJZ-UHFFFAOYSA-N 1-phenyl-1,2,3,4-tetrahydroisoquinoline Chemical compound N1CCC2=CC=CC=C2C1C1=CC=CC=C1 PRTRSEDVLBBFJZ-UHFFFAOYSA-N 0.000 description 1
- AKVCHYGHEAZANX-UHFFFAOYSA-N 1-phenyl-2,3-dihydro-1h-isoindole Chemical compound C12=CC=CC=C2CNC1C1=CC=CC=C1 AKVCHYGHEAZANX-UHFFFAOYSA-N 0.000 description 1
- JFKYAEYYDOTEBD-UHFFFAOYSA-N 1-pyridin-4-yl-1,2,3,4-tetrahydroisoquinoline Chemical compound N1CCC2=CC=CC=C2C1C1=CC=NC=C1 JFKYAEYYDOTEBD-UHFFFAOYSA-N 0.000 description 1
- FHDLSGWIMXIQQV-UHFFFAOYSA-N 1-thiophen-2-yl-1,2,3,4-tetrahydroisoquinoline Chemical compound N1CCC2=CC=CC=C2C1C1=CC=CS1 FHDLSGWIMXIQQV-UHFFFAOYSA-N 0.000 description 1
- MITPAGSWQGXPBC-UHFFFAOYSA-N 1-thiophen-3-yl-1,2,3,4-tetrahydroisoquinoline Chemical compound N1CCC2=CC=CC=C2C1C=1C=CSC=1 MITPAGSWQGXPBC-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- SSUFDOMYCBCHML-UHFFFAOYSA-N CCCCC[S](=O)=O Chemical group CCCCC[S](=O)=O SSUFDOMYCBCHML-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000008017 Hypohidrosis Diseases 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000144290 Sigmodon hispidus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940006460 bromide ion Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- CDEGSGUJXGUBKE-UHFFFAOYSA-N ethyl 1-(4-chlorophenyl)-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound CCOC(=O)N1CCC2=CC=CC=C2C1C1=CC=C(Cl)C=C1 CDEGSGUJXGUBKE-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005932 isopentyloxycarbonyl group Chemical group 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- LZCOQTDXKCNBEE-IKIFYQGPSA-N methscopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-IKIFYQGPSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 229960001383 methylscopolamine Drugs 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000004967 organic peroxy acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000005324 oxide salts Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000010344 pupil dilation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000010340 saliva test Methods 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005930 sec-butyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UWYZHKAOTLEWKK-UHFFFAOYSA-N tetrahydro-isoquinoline Natural products C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- WRTMQOHKMFDUKX-UHFFFAOYSA-N triiodide Chemical compound I[I-]I WRTMQOHKMFDUKX-UHFFFAOYSA-N 0.000 description 1
- 229940006158 triiodide ion Drugs 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K19/00—Liquid crystal materials
- C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
- C09K19/06—Non-steroidal liquid crystal compounds
- C09K19/34—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
- C09K19/3441—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom
- C09K19/3444—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom the heterocyclic ring being a six-membered aromatic ring containing one nitrogen atom, e.g. pyridine
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Urology & Nephrology (AREA)
- Materials Engineering (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
- Tea And Coffee (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6/327045 | 1994-12-28 | ||
| JP32704594 | 1994-12-28 | ||
| PCT/JP1995/002713 WO1996020194A1 (en) | 1994-12-28 | 1995-12-27 | Novel quinuclidine derivatives and medicinal composition thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU97112907A RU97112907A (ru) | 1999-06-27 |
| RU2143432C1 true RU2143432C1 (ru) | 1999-12-27 |
Family
ID=18194699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU97112907/04A RU2143432C1 (ru) | 1994-12-28 | 1995-12-27 | Новые производные хинуклидина и медицинские композиции, содержащие их |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US6017927A (enExample) |
| EP (1) | EP0801067B1 (enExample) |
| JP (1) | JP3014457B2 (enExample) |
| KR (1) | KR100386487B1 (enExample) |
| CN (1) | CN1045601C (enExample) |
| AT (1) | ATE233761T1 (enExample) |
| AU (1) | AU695616B2 (enExample) |
| CA (1) | CA2208839C (enExample) |
| DE (2) | DE122004000048I2 (enExample) |
| DK (1) | DK0801067T3 (enExample) |
| ES (1) | ES2193208T3 (enExample) |
| FI (1) | FI115631B (enExample) |
| FR (1) | FR04C0032I2 (enExample) |
| HU (1) | HU223778B1 (enExample) |
| LU (1) | LU91133I9 (enExample) |
| MX (1) | MX9704880A (enExample) |
| NL (1) | NL300141I2 (enExample) |
| NO (4) | NO2005012I1 (enExample) |
| NZ (1) | NZ298144A (enExample) |
| PL (1) | PL182344B1 (enExample) |
| PT (1) | PT801067E (enExample) |
| RU (1) | RU2143432C1 (enExample) |
| TW (1) | TW305842B (enExample) |
| WO (1) | WO1996020194A1 (enExample) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2290929C2 (ru) * | 2001-07-10 | 2007-01-10 | Астеллас Фарма Инк. | Фармацевтическая композиция для лечения интерстициального цистита |
| RU2296762C2 (ru) * | 2000-12-22 | 2007-04-10 | Альмиралль Продесфарма Аг | Карбаматы хинуклидина, способы их получения и фармацевтическая композиция на их основе |
| RU2314306C2 (ru) * | 2002-07-02 | 2008-01-10 | Альмираль АГ | Производные хинуклидинамида, способ их получения и их применение, фармацевтическая композиция, комбинированный продукт и способ ингибирования мускариновых рецепторов |
| RU2321588C2 (ru) * | 2002-06-21 | 2008-04-10 | Альмираль АГ | Карбаматные производные хинуклидина, фармацевтическая композиция на их основе и применение |
| RU2372350C2 (ru) * | 2004-04-14 | 2009-11-10 | Астразенека Аб | НОВЫЕ ПРОИЗВОДНЫЕ 2-(1-АЗА-БИЦИКЛО[2.2.2]ОКТ-3-ИЛ)-2,3-ДИГИДРОИЗОИНДОЛ-1-ОНА/5,6-ДИГИДРО-ФУРО[2,3-c]ПИРРОЛ-4-ОНА В КАЧЕСТВЕ ЛИГАНДОВ К АЛЬФА 7 НИКОТИНОВОМУ АЦЕТИЛХОЛИНОВОМУ РЕЦЕПТОРУ |
| RU2418797C2 (ru) * | 2004-12-22 | 2011-05-20 | Мемори Фармасьютиклз Корпорейшн | Лиганды никотинового рецептора альфа-7, их получение и применение |
| RU2641285C2 (ru) * | 2013-07-13 | 2018-01-17 | Бэйцзин Фсвэлкам Текнолоджи Девелопмент Ко., Лтд | Соединения хинина, способ их получения и их медицинское применение |
| RU2661877C2 (ru) * | 2012-12-06 | 2018-07-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100137358A1 (en) * | 1996-11-05 | 2010-06-03 | Dr. Reddy's Laboratories Ltd. | Solifenacin compositions |
| WO2008128028A2 (en) * | 2007-04-11 | 2008-10-23 | Dr. Reddy's Laboratories Ltd. | Solifenacin compositions |
| FR2772378B1 (fr) * | 1997-12-12 | 2000-02-04 | Synthelabo | Derives d'imidazole, leur preparation et leur application en therapeutique |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US7214687B2 (en) | 1999-07-14 | 2007-05-08 | Almirall Ag | Quinuclidine derivatives and medicinal compositions containing the same |
| JP2001316670A (ja) * | 2000-05-02 | 2001-11-16 | Dainippon Ink & Chem Inc | 液晶組成物 |
| AU6610001A (en) * | 2000-06-27 | 2002-01-08 | S A L V A T Lab Sa | Carbamates derived from arylalkylamines |
| CN1250545C (zh) | 2000-12-28 | 2006-04-12 | 阿尔米雷尔普罗迪斯制药有限公司 | 新的奎宁环衍生物类及含有这类衍生物的药物组合物 |
| JP4505227B2 (ja) | 2001-12-20 | 2010-07-21 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用 |
| CA2487899A1 (en) * | 2002-06-07 | 2003-12-18 | Yamanouchi Pharmaceutical Co., Ltd. | Overactive bladder treating drug |
| NZ537584A (en) | 2002-07-08 | 2006-07-28 | Ranbaxy Lab Ltd | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
| WO2004014853A1 (en) | 2002-07-31 | 2004-02-19 | Ranbaxy Laboratories Limited | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
| AU2002321711A1 (en) | 2002-08-09 | 2004-02-25 | Ranbaxy Laboratories Limited | 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives useful as muscarinic receptor antagonist |
| JP2006501236A (ja) | 2002-08-23 | 2006-01-12 | ランバクシー ラボラトリーズ リミテッド | ムスカリン性レセプター拮抗薬としてのフルオロおよびスルホニルアミノ含有３，６−二置換アザビシクロ（３．１．０）ヘキサン誘導体 |
| JP2006511494A (ja) * | 2002-10-29 | 2006-04-06 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 抗ムスカリン剤としてのキヌクリジニウム誘導体 |
| US7232835B2 (en) | 2002-12-10 | 2007-06-19 | Ranbaxy Laboratories Limited | 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists |
| DE60315258T2 (de) * | 2002-12-20 | 2008-05-08 | Dynogen Pharmaceuticals Inc., Waltham | Behandlung von nicht-schmerzhaften blasenstörungen mit modulatoren der alpha-2-delta-untereinheit des calciumkanals |
| AU2002347553A1 (en) * | 2002-12-23 | 2004-07-14 | Ranbaxy Laboratories Limited | Flavaxate derivatives as muscarinic receptor antagonists |
| AU2002347552A1 (en) | 2002-12-23 | 2004-07-14 | Ranbaxy Laboratories Limited | 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists |
| US7488748B2 (en) | 2003-01-28 | 2009-02-10 | Ranbaxy Laboratories Limited | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| EP1492519B1 (en) * | 2003-03-21 | 2006-11-15 | Dynogen Pharmaceuticals, Inc. | Methods for treating lower urinary tract disorders using antimuscarinics and alpha-2-delta subunit calcium channel modulators |
| WO2004089898A1 (en) | 2003-04-09 | 2004-10-21 | Ranbaxy Laboratories Limited | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| AU2003223010A1 (en) | 2003-04-10 | 2004-11-01 | Ranbaxy Laboratories Limited | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| CA2521788A1 (en) | 2003-04-10 | 2004-10-21 | Ranbaxy Laboratories Limited | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| BRPI0409302A (pt) | 2003-04-11 | 2006-04-11 | Ranbaxy Lab Ltd | derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos |
| WO2004091597A2 (en) * | 2003-04-15 | 2004-10-28 | Pharmacia & Upjohn Company Llc | Method of treating irritable bowel syndrome (ibs) |
| US20050175689A1 (en) * | 2003-10-27 | 2005-08-11 | Yamanouchi Pharmaceutical Co., Ltd. | Coated fine particles containing drug for intrabuccally fast disintegrating tablet |
| EP1714965A4 (en) * | 2004-02-09 | 2007-12-19 | Astellas Pharma Inc | COMPOSITION CONTAINING SOLIFENACINE SUCCINATE |
| WO2005077364A1 (ja) * | 2004-02-18 | 2005-08-25 | Yamanouchi Pharmaceutical Co., Ltd. | ソリフェナシンの経皮投与製剤およびその経皮透過改善方法 |
| ES2239546B1 (es) * | 2004-03-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos esteres de quinuclidina cuaternizados. |
| JPWO2005087231A1 (ja) * | 2004-03-16 | 2008-01-24 | アステラス製薬株式会社 | ソリフェナシン含有組成物 |
| CA2560080A1 (en) * | 2004-03-16 | 2005-09-22 | Astellas Pharma Inc. | Solifenacin-containing composition |
| CN1934109B (zh) * | 2004-03-25 | 2010-06-23 | 安斯泰来制药株式会社 | 用于固体制剂的索非那新或其盐的组合物 |
| MXPA06010908A (es) * | 2004-03-25 | 2006-12-15 | Astellas Pharma Inc | Composicion para la preparacion farmaceutica solida de solifenacina o una sal de la misma. |
| WO2006035280A1 (en) * | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases |
| WO2006035303A1 (en) * | 2004-09-29 | 2006-04-06 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| RU2397767C2 (ru) * | 2004-12-27 | 2010-08-27 | Астеллас Фарма Инк. | Стабильная, состоящая из частиц фармацевтическая композиция, содержащая солифенацин или его соль |
| AU2005320672B2 (en) * | 2004-12-27 | 2011-01-06 | Astellas Pharma Inc. | Stable particulate pharmaceutical composition of solifenacin or salt thereof |
| CA2599158C (en) * | 2005-02-25 | 2011-01-25 | Astellas Pharma Inc. | Pharmaceutical agent comprising solifenacin |
| JP3701964B1 (ja) * | 2005-03-08 | 2005-10-05 | アステラス製薬株式会社 | キヌクリジン誘導体の新規な塩 |
| US20080255188A1 (en) * | 2005-07-11 | 2008-10-16 | Naresh Kumar | Muscarinic Receptor Antagonists |
| US7815939B2 (en) | 2005-07-20 | 2010-10-19 | Astellas Pharma Inc. | Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms |
| WO2007045979A1 (en) | 2005-10-19 | 2007-04-26 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of muscarinic receptor antagonists |
| EP1879867A2 (en) * | 2005-12-21 | 2008-01-23 | Teva Pharmaceutical Industries Ltd | Intermediates for preparing solifenacin |
| CZ300699B6 (cs) * | 2006-06-21 | 2009-07-22 | Zentiva, A. S. | Zpusob prípravy solifenacinu |
| US20090326230A1 (en) * | 2006-07-19 | 2009-12-31 | Dr. Reddy's Laboratories Ltd. | Process for preparing solifenacin and its salts |
| ES2298049B1 (es) * | 2006-07-21 | 2009-10-20 | Laboratorios Almirall S.A. | Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano. |
| US20080114028A1 (en) * | 2006-07-24 | 2008-05-15 | Tamas Koltai | Process for preparing polymorphic forms of solifenacin succinate |
| EP1945636A2 (en) * | 2006-08-03 | 2008-07-23 | Teva Pharmaceutical Industries Ltd. | Polymorphs of solifenacin intermediate |
| TW200825084A (en) * | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| EP2102200A2 (en) * | 2006-11-22 | 2009-09-23 | Medichem, S.A. | An improved process for the synthesis of solifenacin |
| CZ300692B6 (cs) * | 2006-12-22 | 2009-07-15 | Zentiva, A. S. | Zpusob prípravy solifenacinu |
| CN101711248A (zh) * | 2007-03-30 | 2010-05-19 | 医药化学公司 | 一种改进的素非那新合成工艺 |
| WO2009011844A1 (en) * | 2007-07-13 | 2009-01-22 | Teva Pharmaceutical Industries Ltd. | Processes for solifenacin preparation |
| KR20100040294A (ko) | 2007-07-20 | 2010-04-19 | 아스텔라스세이야쿠 가부시키가이샤 | 전립선 비대에 수반되는 하부 요로 증상의 개선용 의약 조성물 |
| EP2018850A1 (en) * | 2007-07-24 | 2009-01-28 | Ratiopharm GmbH | Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof |
| PT2216021E (pt) * | 2007-11-02 | 2012-11-06 | Astellas Pharma Inc | Composição farmacêutica para tratar uma bexiga hiperactiva |
| EP2229387A1 (en) * | 2007-12-04 | 2010-09-22 | Cadila Healthcare Limited | Process for preparing chemically and chirally pure solifenacin base and its salts |
| WO2009073203A1 (en) * | 2007-12-04 | 2009-06-11 | Amgen Inc. | Trp-m8 receptor ligands and their use in treatments |
| ITMI20080195A1 (it) | 2008-02-08 | 2009-08-09 | Dipharma Francis Srl | Procedimento per la preparazione di solifenacin |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP4088717A1 (en) | 2008-03-27 | 2022-11-16 | Chase Pharmaceuticals Corporation | Use and composition for treating dementia |
| PL385264A1 (pl) | 2008-05-23 | 2009-12-07 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Sposób wytwarzania enancjomerycznie czystej (S)-1-fenylo-1, 2, 3, 4-tetrahydroizochinoliny |
| PL385265A1 (pl) | 2008-05-23 | 2009-12-07 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej |
| SI3067353T1 (en) | 2008-07-29 | 2018-03-30 | Krka, D.D., Novo Mesto | Process for the preparation of solifenacin salts and their inclusion in pharmaceutical dosage forms |
| EP2181707A1 (en) | 2008-11-04 | 2010-05-05 | Astellas Ireland Co., Ltd. | Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent |
| SG173528A1 (en) * | 2009-02-04 | 2011-09-29 | Astellas Pharma Inc | Pharmaceutical composition for oral administration |
| US8283470B2 (en) | 2009-03-09 | 2012-10-09 | Megafine Pharma(P) Ltd. | Method for the preparation of solifenacin and intermediate thereof |
| WO2010113840A1 (ja) | 2009-03-30 | 2010-10-07 | アステラス製薬株式会社 | ソリフェナシン非晶質体を含有した固形医薬組成物 |
| WO2011048607A1 (en) | 2009-09-25 | 2011-04-28 | Cadila Healthcare Limited | Processes for the preparation of solifenacin or a salt thereof |
| PL234208B1 (pl) | 2010-01-18 | 2020-01-31 | Zakl Farmaceutyczne Polpharma Spolka Akcyjna | Sposób wytwarzania bursztynianu solifenacyny |
| EP2554184B1 (en) | 2010-03-31 | 2016-10-26 | ONO Pharmaceutical Co., Ltd. | Preventive and/or remedy for hand and foot syndrome |
| AU2011245499B2 (en) | 2010-04-30 | 2014-09-25 | Merck Sharp & Dohme Corp. | Novel beta 3 adrenergic receptor agonists |
| PH12012502132A1 (en) | 2010-05-19 | 2013-02-04 | Astellas Pharma Inc | Pharmaceutical composition containing solifenacin |
| WO2012001481A1 (en) | 2010-06-28 | 2012-01-05 | Aurobindo Pharma Limited | Novel process for the preparation of solifenacin succinate |
| US8765785B2 (en) | 2010-07-05 | 2014-07-01 | Crystal Pharma, S.A.U. | Solifenacin salts |
| EP2638039A1 (de) | 2010-11-11 | 2013-09-18 | Hexal AG | Kristallines solifenacin-succinat |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| WO2012154774A1 (en) | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder |
| JP2014520126A (ja) | 2011-06-22 | 2014-08-21 | イソケム | ソリフェナシンおよびその塩の製造方法 |
| KR101365849B1 (ko) | 2012-03-28 | 2014-02-24 | 경동제약 주식회사 | 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체 |
| CN104411687A (zh) * | 2012-07-02 | 2015-03-11 | 法尔玛赞公司 | 一种用于制备索非那新或其盐的方法 |
| EP2891493A4 (en) | 2012-08-31 | 2016-05-18 | Astellas Pharma Inc | MEDICAL COMPOSITION ADMINISTERED ORALLY |
| KR20200065113A (ko) | 2012-09-05 | 2020-06-08 | 체이스 파마슈티칼스 코포레이션 | 항콜린 신경보호 조성물 및 그 방법 |
| CN103787969B (zh) | 2012-10-30 | 2016-07-06 | 上海京新生物医药有限公司 | 一种(1s)-1-苯基-3,4-二氢-2（1h）-异喹啉甲酸酯的制备方法 |
| EP2778167A1 (en) | 2013-03-11 | 2014-09-17 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt |
| EP3139924A4 (en) | 2014-05-06 | 2018-03-07 | Anthony G. Visco | Methods of treating or preventing preterm labor |
| CN104592221A (zh) * | 2015-01-26 | 2015-05-06 | 中山奕安泰医药科技有限公司 | 一种合成索非那新的工艺 |
| KR20160146428A (ko) | 2015-06-12 | 2016-12-21 | 한미정밀화학주식회사 | 솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법 |
| KR102148414B1 (ko) | 2017-05-15 | 2020-08-26 | 주식회사 서울제약 | 솔리페나신을 유효성분으로 하는 구강붕해필름 |
| TW201927783A (zh) | 2017-12-12 | 2019-07-16 | 美商阿爾庫達醫療公司 | 顆粒體蛋白前體調節劑及其使用方法 |
| HUE068695T2 (hu) | 2018-05-08 | 2025-01-28 | Nippon Shinyaku Co Ltd | Azabenzimidazol vegyületek és gyógyszerek |
| US20220251084A1 (en) * | 2019-06-12 | 2022-08-11 | Arkuda Therapeutics | Progranulin modulators and methods of using the same |
| US12528813B2 (en) | 2019-11-13 | 2026-01-20 | Nippon Shinyaku Co., Ltd. | Substituted imidazo[4,5-b]pyridines as M3 receptor PAMs |
| CN113200979A (zh) * | 2021-04-13 | 2021-08-03 | 上海予君生物科技发展有限公司 | 一种琥珀酸索非那新的合成工艺 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0404737A2 (en) * | 1989-06-20 | 1990-12-27 | BOEHRINGER INGELHEIM ITALIA S.p.A. | New R(-) 3-quinuclidinol derivatives |
| EP0382687A3 (en) * | 1989-02-06 | 1991-12-04 | BOEHRINGER INGELHEIM ITALIA S.p.A. | Benzofused-n-containing heterocycle derivatives |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3687980T2 (de) * | 1986-01-07 | 1993-06-17 | Beecham Group Plc | Indolderivate mit einer azabicyclischen seitenkette, verfahren zu ihrer herstellung, zwischenprodukte und pharmazeutische zusammensetzungen. |
| IT1231238B (it) * | 1987-09-21 | 1991-11-26 | Angeli Inst Spa | Derivati ammidinici |
| GB9023023D0 (en) * | 1990-10-23 | 1990-12-05 | Barlow Richard B | Pharmaceutical compositions |
| GB9202443D0 (en) * | 1992-02-05 | 1992-03-18 | Fujisawa Pharmaceutical Co | A novel substituted-acetamide compound and a process for the preparation thereof |
| JPH076635A (ja) * | 1993-06-18 | 1995-01-10 | Sony Corp | 信号伝送ケーブル |
| WO1995006635A1 (en) * | 1993-09-02 | 1995-03-09 | Yamanouchi Pharmaceutical Co., Ltd. | Carbamate derivative and medicine containing the same |
| JPH07258250A (ja) * | 1994-03-25 | 1995-10-09 | Yamanouchi Pharmaceut Co Ltd | エステル誘導体 |
| EP1424021B1 (en) * | 2002-11-27 | 2006-09-13 | Selmac S.r.l. | Device for positioning and clamping shaped elements and machine equipped with this device |
-
1988
- 1988-09-19 NO NO2005012C patent/NO2005012I1/no unknown
-
1995
- 1995-12-27 NZ NZ298144A patent/NZ298144A/en not_active IP Right Cessation
- 1995-12-27 PT PT95942276T patent/PT801067E/pt unknown
- 1995-12-27 HU HU9701895A patent/HU223778B1/hu active Protection Beyond IP Right Term
- 1995-12-27 CA CA002208839A patent/CA2208839C/en not_active Expired - Lifetime
- 1995-12-27 AU AU43553/96A patent/AU695616B2/en not_active Expired
- 1995-12-27 ES ES95942276T patent/ES2193208T3/es not_active Expired - Lifetime
- 1995-12-27 RU RU97112907/04A patent/RU2143432C1/ru active Protection Beyond IP Right Term
- 1995-12-27 KR KR1019970703649A patent/KR100386487B1/ko not_active Expired - Lifetime
- 1995-12-27 TW TW084113934A patent/TW305842B/zh not_active IP Right Cessation
- 1995-12-27 CN CN95197088A patent/CN1045601C/zh not_active Expired - Lifetime
- 1995-12-27 DE DE200412000048 patent/DE122004000048I2/de active Active
- 1995-12-27 NL NL300141C patent/NL300141I2/nl unknown
- 1995-12-27 JP JP8520367A patent/JP3014457B2/ja not_active Expired - Lifetime
- 1995-12-27 PL PL95321019A patent/PL182344B1/pl unknown
- 1995-12-27 AT AT95942276T patent/ATE233761T1/de active
- 1995-12-27 MX MX9704880A patent/MX9704880A/es unknown
- 1995-12-27 WO PCT/JP1995/002713 patent/WO1996020194A1/ja not_active Ceased
- 1995-12-27 DE DE69529844T patent/DE69529844T2/de not_active Expired - Lifetime
- 1995-12-27 DK DK95942276T patent/DK0801067T3/da active
- 1995-12-27 EP EP95942276A patent/EP0801067B1/en not_active Expired - Lifetime
- 1995-12-27 US US08/860,377 patent/US6017927A/en not_active Expired - Lifetime
-
1997
- 1997-06-27 NO NO19973027A patent/NO318026B1/no not_active IP Right Cessation
- 1997-06-27 FI FI972775A patent/FI115631B/fi active Protection Beyond IP Right Term
-
1999
- 1999-05-14 US US09/312,392 patent/US6174896B1/en not_active Expired - Lifetime
-
2004
- 2004-12-30 FR FR04C0032C patent/FR04C0032I2/fr active Active
-
2005
- 2005-01-28 LU LU91133C patent/LU91133I9/fr unknown
- 2005-07-11 NO NO2005016C patent/NO2005016I2/no unknown
-
2017
- 2017-11-06 NO NO2017055C patent/NO2017055I2/no unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0382687A3 (en) * | 1989-02-06 | 1991-12-04 | BOEHRINGER INGELHEIM ITALIA S.p.A. | Benzofused-n-containing heterocycle derivatives |
| EP0404737A2 (en) * | 1989-06-20 | 1990-12-27 | BOEHRINGER INGELHEIM ITALIA S.p.A. | New R(-) 3-quinuclidinol derivatives |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2296762C2 (ru) * | 2000-12-22 | 2007-04-10 | Альмиралль Продесфарма Аг | Карбаматы хинуклидина, способы их получения и фармацевтическая композиция на их основе |
| RU2290929C2 (ru) * | 2001-07-10 | 2007-01-10 | Астеллас Фарма Инк. | Фармацевтическая композиция для лечения интерстициального цистита |
| RU2321588C2 (ru) * | 2002-06-21 | 2008-04-10 | Альмираль АГ | Карбаматные производные хинуклидина, фармацевтическая композиция на их основе и применение |
| RU2314306C2 (ru) * | 2002-07-02 | 2008-01-10 | Альмираль АГ | Производные хинуклидинамида, способ их получения и их применение, фармацевтическая композиция, комбинированный продукт и способ ингибирования мускариновых рецепторов |
| RU2372350C2 (ru) * | 2004-04-14 | 2009-11-10 | Астразенека Аб | НОВЫЕ ПРОИЗВОДНЫЕ 2-(1-АЗА-БИЦИКЛО[2.2.2]ОКТ-3-ИЛ)-2,3-ДИГИДРОИЗОИНДОЛ-1-ОНА/5,6-ДИГИДРО-ФУРО[2,3-c]ПИРРОЛ-4-ОНА В КАЧЕСТВЕ ЛИГАНДОВ К АЛЬФА 7 НИКОТИНОВОМУ АЦЕТИЛХОЛИНОВОМУ РЕЦЕПТОРУ |
| RU2418797C2 (ru) * | 2004-12-22 | 2011-05-20 | Мемори Фармасьютиклз Корпорейшн | Лиганды никотинового рецептора альфа-7, их получение и применение |
| RU2661877C2 (ru) * | 2012-12-06 | 2018-07-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов |
| RU2641285C2 (ru) * | 2013-07-13 | 2018-01-17 | Бэйцзин Фсвэлкам Текнолоджи Девелопмент Ко., Лтд | Соединения хинина, способ их получения и их медицинское применение |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0801067B1 (en) | Novel quinuclidine derivatives and medicinal composition thereof | |
| US7078409B2 (en) | Fused quinazoline derivatives useful as tyrosine kinase inhibitors | |
| WO1995006635A1 (en) | Carbamate derivative and medicine containing the same | |
| EP0747355A1 (en) | Novel carbamate derivative and medicinal composition containing the same | |
| EP0915094B1 (en) | Morphinane derivatives and medicinal use thereof | |
| WO1997047601A1 (en) | Fused heterocyclic compounds and medicinal uses thereof | |
| HRP980157A2 (en) | Ultra short acting neuromuscular blockers | |
| EP0453197B1 (en) | Amine derivatives | |
| US5968949A (en) | Substituted hydroisoquinoline derivatives and their use as pharmaceuticals | |
| JP2003267977A (ja) | キヌクリジン誘導体 | |
| US5441956A (en) | Hydroisoquinoline derivatives | |
| KR19990077033A (ko) | Cns 활성을 갖는 4,5-디히드로나프트[1,2-c]이속사졸 및그의 유도체 | |
| DK161200B (da) | 11-substituerede 5,11-dihydro-6h-pyridooe2,3-baaoe1,4aa-benzodiazepin-6-oner, fremgangsmaade til fremstilling heraf, laegemiddel indeholdende en saadan forbindelse samt anvendelse af en saadan forbindelse tilfremstilling af laegemidler | |
| JP2000109481A (ja) | キヌクリジン誘導体含有医薬 | |
| JPWO1996020194A1 (ja) | 新規キヌクリジン誘導体及びその医薬組成物 | |
| RU2418794C2 (ru) | ПРОИЗВОДНЫЕ ИЗОХИНОЛИНА И БЕНЗО[h]ИЗОХИНОЛИНА, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА ГИСТАМИНА H3 | |
| JPH0240381A (ja) | 新規縮合ジアゼピノン類、それらの製造方法及びこれらの化合物を含有する医薬組成物 | |
| JP2002542247A (ja) | モルフィノイド化合物 | |
| JPH107675A (ja) | 新規なイソキノリン誘導体又はその塩 | |
| JP2003081978A (ja) | スピロ環式化合物およびその医薬用途 | |
| JPS624288A (ja) | 新規なジアゼピノン化合物 | |
| JP3007675B2 (ja) | 新規なインドール誘導体 | |
| JPWO1995021820A1 (ja) | 新規なカルバメート誘導体及びその医薬組成物 | |
| JP2004511487A (ja) | ピロール−縮合モルフィノイド誘導体 | |
| PAIN | United States Patent po |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner | ||
| RH4A | Copy of patent granted that was duplicated for the russian federation |
Effective date: 20060417 |
|
| ND4A | Extension of patent duration | ||
| TK4A | Correction to the publication in the bulletin (patent) |
Free format text: AMENDMENT TO CHAPTER -ND4A- IN JOURNAL: 31-2006 |
|
| PD4A | Correction of name of patent owner |